Marcel Hop

About Marcel Hop

Strong scientific and management skills to facilitate project advancement in drug discovery and development. Member of various strategic decision making bodies for both small and large molecules and effective leader of external collaborations.• Forged excellent interactions within the DMPK department and between DMPK and other departments in drug discovery and development, in particular Medicinal Chemistry, Safety Assessment and Clinical Pharmacology.• Identified and pursued opportunities to increase the strategic impact of ADME sciences in drug discovery and development (including change management).• Extensive experience evaluating in-licensing and other business development opportunities.• Supervision and talent development of all scientists resulting in a high level of engagement. Instill a high level of scientific excellence and innovation resulting in internal impact and external visibility.As a member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases.Diversity and Inclusion (D&I) are critical to the success of our company and our impact on society. We believe that by championing diversity of background, thought and experience, we can foster a sense of belonging and provide an environment where every employee feels valued, included, and able to contribute their best for the patients we serve. We’re focused on attracting, retaining, developing and advancing our people to their full potential by rewarding bold ways of thinking and integrating inclusive behaviors into every aspect of our work.

Experience

1. Vice President

   Genentech

   Jun 2019 — Present

   Vice President and leader of small molecule Drug Metabolism & Pharmacokinetics (DMPK) department at Genentech. Member of the small molecule leadership team chartered with management of the whole small molecule portfolio and strategic planning. Member of the Research Review Committee and Development Review Committee managing the discovery and development portfolio – small and large molecules. Management of a team of about 85 scientists involved in generation and interpretation of ADME data in support of drug discovery and development projects ranging from early stage research to post marketing commitments. Accountable for ADME portion of internal decision-making documents and regulatory documents. Responsible for strategic direction of DMPK department with emphasis on improving efficiency and reducing ADME-related attrition as well as internal and external staffing, budget management and performance evaluation. Strategic planning for near-term and long-term opportunities for computational sciences to impact drug discovery.

Education

• Utrecht University

  PhD, Chemistry

  1986 — 1988

Skills

• Drug Design
• Adme
• Lc-Ms
• Life Sciences
• Drug Metabolism
• Pharmaceutical Industry
• Small Molecules
• Glp
• Dmpk
• Drug Development
• Drug Discovery
• Bioanalysis
• Biopharmaceuticals
• Lead Change
• Pharmacology
• Clinical Development
• Lifesciences
• Hplc
• Strategic Planning
• Lead Optimization
• Pharmaceuticals
• Biotechnology
• Pharmacokinetics
• Pharmacodynamics